1. Chronic myeloid leukaemia at the Kenyatta National Hospital, Nairobi.
- Author
-
Othieno-Abinya NA, Nyabola LO, Kiarie GW, Ndege R, and Maina JM
- Subjects
- Adolescent, Adult, Age Distribution, Aged, Antineoplastic Agents, Alkylating administration & dosage, Busulfan administration & dosage, Child, Female, Humans, Hydroxyurea administration & dosage, Kenya, Leukemia, Myelogenous, Chronic, BCR-ABL Positive blood, Leukemia, Myelogenous, Chronic, BCR-ABL Positive complications, Leukemia, Myelogenous, Chronic, BCR-ABL Positive diagnosis, Leukocyte Count, Male, Middle Aged, Retrospective Studies, Severity of Illness Index, Splenomegaly classification, Splenomegaly etiology, Survival Analysis, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Leukemia, Myelogenous, Chronic, BCR-ABL Positive epidemiology
- Abstract
Objective: To determine the clinical and haematological factors associated with treatment and outcome of chronic myeloid leukaemia (CML) at Kenyatta National Hospital., Design: Retrospective survey of patients treated for chronic myeloid leukaemia., Setting: Kenyatta National hospital, Nairobi, Kenya, between April 1990 and August 2000., Subjects: Patients with chronic myeloid leukaemia., Results: One hundred and four patients, 55 males and 49 females, age range 10-72 years with a median age of 35 years. Treatment with busulphan getting less popular in favour of hydroxyurea. Median follow-up 20 months with none of the clinical and haematological parameters impacting significantly on duration of follow-up., Conclusion: CML occurs at a younger age-group in Kenya, and none of the clinical or haematological parameters appears to impact on follow-up duration.
- Published
- 2002
- Full Text
- View/download PDF